CI-WXAT@EC2701A

WuXi AppTec Reports Record Operational Performance in 2025 Annual Report

China Renaissance Maintains Buy Rating on WuXi

JPMorgan Raises 2026-2028 Sales Forecast and Target Price for Wuxi Biologics

WuXi Biologics Reports in Line with Expectations, CLSA Raises Target Price

CICC: Wuxi Biologics Meets Earnings Expectations in 2025

CLSA Raises Net Profit Forecast and Adjusts Target Price for Wuxi Biologics

Goldman Sachs Publishes Report on Wuxi Biologics' Performance and Future Growth Projections

UBS Publishes Analysis Report on Wuxi Biologics' Performance

WuXi AppTec plans to use 1.8 billion yuan of idle funds for cash management

WuXi AppTec to Provide for Impairment Loss of 1.07 billion yuan in 2025

WuXi AppTec Plans to Provide Up to 1.5 Billion Yuan in Guarantees for Subsidiaries

WuXi Biologics Proposes to Adopt 2026 H-Share Incentive Trust Plan

WuXi Biologics Shareholders to Vote on H-Share Incentive and Trust Plan Amendments

WuXi AppTec Reports Net Profit Growth of 105.2% YoY

WUXI APPTEC released FY2025 Q4 earnings on March 23 During-Market (BJT), actual revenue HKD 12.2 B (forecast HKD 13.61 B), actual EPS HKD 2.6366 (forecast HKD 1.8643)

WUXI APPTEC released FY2025 Annual Earnings on March 23 During-Market (BJT), actual revenue HKD 0 (forecast HKD 49.82 B), actual EPS HKD 0 (forecast HKD 6.5892)

WUXI XDC and WUXI APPTEC Shares Rise in Hong Kong

WUXI APPTEC to Release FY2025 Earnings on March 23 Pre-Market (BJT), Forecast Revenue HKD 50.79 B, EPS HKD 6.7342

JPMorgan Increases Stake in WuXi Biologics H Shares

Morgan Stanley Raises Profit Forecast and Rating for Wuxi Biologics

ASIA TELE-NET

WAI CHUN GROUP

SILKWAVE INC

SHEUNG YUE GP

POLYFAIR HLDGS

BGMC International

CEC INT'L HOLD

RONGZHONG FIN

ECHO INT HOLD

09866

01776

09660

00992

01179

06656

03986

02359

03317

06869

NIO-SW(09866) rose 3.42%, with a trading turnover 239.3 Million HKD, and a year-to-date rose 33.1%. GF SEC(01776) rose 3.2%, with a trading turnover 321.7 Million HKD, and a year-to-date fell 1.2%. SIGENERGY(06656) fell 9.02%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 85.1%. GIGADEVICE(03986) fell 6.83%, with a trading turnover 894.9 Million HKD, and a year-to-date rose 165.9%.

- The Hang Seng Index fell by 0.89%, with a year-to-date increase of 2.1%.  
- The Hang Seng Tech Index decreased by 0.97%, showing an annual decline of 8.6%.  
- Notable movements included NIO rising by 3.42% and Zhaoyi Innovation dropping by 6.83%, reflecting significant annual gains and losses respectively.

Top Gainers & Losers

NIO-SW

GF SEC

HORIZONROBOT-W

LENOVO GROUP

HWORLD-S

SIGENERGY

GIGADEVICE

WUXI APPTEC

XUNCE

YOFC

Top 5 HK Stock Gainers/Losers (>100B) (4.17)

513700

00460

513120

159570

520880

159316

520500

520690

Hong Kong's innovative drug sector is experiencing significant growth, with companies like Ascletis Pharmaincreasing over 3% and Hansoh Pharmaceuticalrising by more than 2%. Other firms, including WuXi AppTecand Sihuan Pharmaceutical, are also showing upward trends.

CoinLive

Penghua CSI HK Connect Health Care Composite ETF

SIHUAN PHARM

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

HANSOH PHARMA

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

ASCLETIS-B

Hong Kong's Innovative Drug Sector Gains Momentum

LABU

IBBQ

603259

Ahead of the upcoming American Association for Cancer Research (AACR) annual meeting and the American Society of Clinical Oncology (ASCO) annual meeting, biopharmaceutical stocks have performed well, particularly Beigene and WuXi AppTec. Beigene is expected to achieve a net profit of $287 million in 2025, with total annual revenue of $5.343 billion, a growth of 40%. Its main product, "Tislelizumab," has performed exceptionally well in the European and American markets, driving revenue growth. The company has also achieved significant income from external licensing, with innovative drug licensing deals exceeding $60 billion in the first quarter

Stheadline

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Beigene

BEONE MEDICINES

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

BeOne Medicines

WuXi AppTec

Ark Genomic Revolution ETF

iShares Biotechnology ETF

iShares Global Healthcare

Health Care Select Sector SPDR

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

ALPS Medical Breakthrough

VG Health

Innovative drugs welcome the "going abroad" harvest period, with a surge in external licensing amounts. Beigene turns losses into profits, and WuXi AppTec sees a significant increase in orders. | Investment Pursuit

FTXG

603288

159736

159843

159735

513230

513070

09987

Goldman Sachs has added Yum China ADR, WuXi AppTec, and HAI TIAN stocks to the Asia-Pacific "Conviction Buy List," while removing Toyo Tire and MakeMyTrip from the list. The latest target prices include: Dongpeng Beverage RMB 300, Gu Ming HKD 36, HAI TIAN HKD 46.8, Yum China USD 57.7, WuXi AppTec HKD 149.7, Alibaba USD 186, etc

AASTOCKS

First Trust NASDAQ Food & Beverage

HAI TIAN

Tianhong CSI Food and Beverage ETF

China Merchants Guozheng Food and Beverage ETF

Yinhua CSI HK Equities Consumption Theme ETF

ChinaAMC CSI HK Connect Consumption Theme ETF

E Fund CSI HK Equities Consumption Theme ETF

YUM CHINA

Goldman Sachs adds Yum China ADR, WuXi AppTec, and HAI TIAN to the Asia-Pacific "Conviction Buy List"

513130

01070

EBIZ

On April 1, the Hong Kong stock market saw a collective rise in major indices during intraday trading, with the Hang Seng Index up 2.39% and the Hang Seng Tech Index up 2.64%. The internet content and retail sectors performed strongly, with leading stocks such as Tencent Holdings and Alibaba-W significantly boosting market sentiment. The oil and gas sector, influenced by international oil prices, saw a contrarian pullback. Individual stocks like TCL ELECTRONICS and HANSOH PHARMA were active with robust trading volumes, while the market is closely watching macroeconomic data and changes in consumer confidence

- At midday on April 1, Hong Kong stocks rose, with the Hang Seng Index up 2.39% to 25,379.55 points, though it remains below recent highs.  
- The market observed significant movements in innovative sectors, with notable gains from companies such as Zhiyuan and TCL Electronics, while the energy sector faced pressure, highlighted by a drop in CNOOC shares.  
- Investor focus is shifting towards macroeconomic indicators like manufacturing PMI and unemployment rates amidst ongoing fluctuations in exports and trade.

Market Heartbeat

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

TCL ELECTRONICS

Global X E-commerce ETF

VanEck Retail ETF

CSOP HS TECH

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

Tianhong Hang Seng TECH ETF(QDII)

TENCENT

CI-LEAP@EC2612A

LEAPMOTOR

SUN HUNG KAI CO

CNOOC

KNOWLEDGE ATLAS

XIAOMI-W

BYD COMPANY

MEITUAN

E Fund CSI HK Connect Internet ETF

Alibaba

SPDR S&P Retail ETF

BABA-W

Hong Kong Stocks Intraday | Hang Seng Index Rises 2.39%, Internet Retail Strong

China Renaissance has maintained a Buy rating on WuXi AppTec Co., Ltd. Class H (2359) as of March 27, with a price target of HK$173.00. The stock closed at HK$115.60. The analyst consensus is a Strong Buy with an average price target of HK$152.04, indicating a potential upside of 31.52%. J.P. Morgan also supports this with a Buy rating and a price target of HK$150.00.

Tip Ranks

China Renaissance Keeps Their Buy Rating on WuXi AppTec Co., Ltd. Class H (2359)

159506

J.P. Morgan analyst Yang Huang has maintained a Buy rating on WuXi AppTec Co., Ltd. Class H (2359), setting a price target of HK$150.00. The analyst is ranked #528 out of 12,068 analysts according to TipRanks. The consensus among analysts for WuXi AppTec Co., Ltd. Class H is a Strong Buy, with a price target consensus of HK$146.84.

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

J.P. Morgan Remains a Buy on WuXi AppTec Co., Ltd. Class H (2359)

WuXi AppTec Earnings Call Signals Confident 2026 Path

WuXi AppTec Earnings Call Signals Confident 2026 Path

159615

516500

159837

588130

562050

510660

516930

512290

CICC released a report stating that WuXi AppTec's 2025 performance meets expectations, with revenue of 45.456 billion RMB, a year-on-year increase of 15.8%; net profit attributable to the parent company is 19.151 billion RMB, a year-on-year increase of 102.7%. It is expected that total revenue in 2026 will reach 51.3 billion to 53 billion RMB, with a continuous growth of operating business revenue by 18%-22%. The net profit forecasts for 2026 and 2027 are maintained at 17.03 billion RMB and 19.13 billion RMB, respectively, with A/H share ratings of "outperforming the industry," and target prices of 123.5 RMB and 135 HKD, respectively

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE Health Care ETF Initiating Fund

WUXI BIO

Penghua SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

CITIC Securities: WuXi AppTec's performance last year met expectations, maintaining earnings forecast

513060

Goldman Sachs raised WuXi AppTec's target price to HKD 149.7, maintaining a "Buy" rating. The company reiterated its revenue growth guidance during the earnings conference, expecting a 22% to 26% increase in revenue from continuing operations this year. Management emphasized that the oral small molecule GLP-1 project will become an important growth driver, with an expectation that 70% of the existing orders can be converted into revenue. Both the TIDES business and small molecule CDMO business have good growth prospects. Goldman Sachs slightly adjusted its earnings per share forecast, raising the A-share target price from RMB 132.7 to RMB 137.3

Bosera Hang Seng Health Care ETF(QDII)

Goldman Sachs raises WuXi AppTec's target price to 149.7 yuan, maintaining a "Buy" rating

Citi raised WuXi AppTec's target price to HKD 156 and listed it as the industry favorite. Management expects revenue growth from continuing operations this year to be between 18% and 22%, or 22% to 26% at constant exchange rates. The TIDES business is expected to grow by 30% to 40%. Citi raised its revenue forecasts for the next two years by 2% and 5%, and introduced a forecast for 2028, maintaining a "Buy" rating

Citigroup raises WuXi AppTec's target price to 156 yuan, listing it as the industry's top pick

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

INNOCARE

InnoCare Pharma

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

CI-WXAT@EC2701A(28374.HK)

CI-WXAT@EC2701A Stock Performance Chart

Top 5 HK Stock Gainers/Losers (>100B) (4.17)

Hong Kong's Innovative Drug Sector Gains Momentum

Innovative drugs welcome the "going abroad" harvest period, with a surge in external licensing amounts. Beigene turns losses into profits, and WuXi AppTec sees a significant increase in orders. | Investment Pursuit

Goldman Sachs adds Yum China ADR, WuXi AppTec, and HAI TIAN to the Asia-Pacific "Conviction Buy List"

Hong Kong Stocks Intraday | Hang Seng Index Rises 2.39%, Internet Retail Strong